Progyny (PGNY) has wrapped up FY 2025 with fourth quarter revenue of US$318.4 million and basic EPS of US$0.15, while trailing 12 month figures show revenue of about US$1.3 billion and EPS of US$0.68 alongside 7.7% earnings growth over the past year. Over recent periods the company has seen quarterly revenue move from US$298.4 million in Q4 2024 to US$318.4 million in Q4 2025, with basic EPS shifting from US$0.12 to US$0.15, and trailing 12 month earnings rising from US$54.3 million to US$58.5 million. This sets up a results season where investors are focused on how much of that improvement can stick given relatively modest net margins.

See our full analysis for Progyny.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely held narratives about Progyny’s growth potential and risk profile, and where those stories might need updating.

TTM earnings growth breaks a five year decline

• Trailing 12 month earnings grew 7.7% to US$58.5 million on revenue of about US$1.3b, after a prior five year period where earnings declined about 2% per year.
• Bulls argue that expanding partnerships and higher utilization can sustain this shift. However, the 4.5% net margin, slightly below last year’s 4.7%, shows that any long term earnings ramp still has to work off relatively thin profitability.
  • The bullish view leans on rising demand for fertility and women’s health benefits and new offerings like pelvic floor therapy and leave navigation, while the latest 7.7% earnings growth provides early support for that story.
  • At the same time, the multi year earnings decline in the recent past and only modest margin level give bears room to question how durable that improvement will be if growth in covered lives or pricing slows.

Bulls point to this earnings inflection as the start of a new phase, while skeptics see it as a test case for whether Progyny can turn modest margins into compounding profit growth over time. 🐂 Progyny Bull Case

Quarter to quarter profit is uneven

• Within FY 2025, quarterly net income moved from US$17.1 million in Q2 to US$12.5 million in Q4, even though revenue held in a fairly tight band between US$313.3 million and US$332.9 million over the year.
• Critics highlight this pattern as fitting the bearish concern that higher costs and competition could pressure profitability, because the 4.5% trailing net margin is already slightly below last year’s 4.7%.
  • The bearish narrative stresses rising healthcare cost pressure and more rivals offering fertility benefits, and the uneven quarterly profit alongside modest margins gives that view some numerical backing.
  • On the other hand, the fact that trailing earnings still grew 7.7% over the year runs against the idea that margin pressure is already causing a broad deterioration in performance.

Skeptics point to the choppy quarterly profit and modest margins as reasons to be cautious on how much of the recent earnings growth can continue. 🐻 Progyny Bear Case

P/E sits between peers and wider healthcare

• Progyny trades on a trailing P/E of 25.6x at a share price of US$19.16, below a 29.8x peer average but above the broader US healthcare sector on 22.4x, while internal estimates cite a DCF fair value of about US$69.52 per share.
• What is striking is how this valuation slotting interacts with both bullish and bearish views, because the analyst price target allowed here of US$27.45 is above the current share price but still far below the DCF fair value figure.
  • Supporters argue that forecasts for earnings growth of about 20.1% per year help justify a P/E premium to the wider healthcare sector and a target above today’s US$19.16 price, especially given the shift from the prior five year earnings decline.
  • By contrast, bears focus on the lower 6.4% revenue growth forecast versus the broader US market’s 11.4% and the 4.5% margin level, and question whether a 25.6x multiple is generous if growth or margin expansion does not match those expectations.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Progyny on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of bullish and bearish takes here, it helps to look at the numbers yourself and pressure test each argument against the data. To see what the current optimism is built on and which rewards investors are watching most closely, check out the 3 key rewards

See What Else Is Out There

Progyny’s thin 4.5% net margin, choppy quarterly profit and earnings only now recovering from a multi year decline all raise questions about durability and resilience.

If that mix of modest profitability and uneven earnings worries you, compare it with companies that score well on resilience using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.